Novo Nordisk has great expectations for the potential launch of its drug, semaglutide, to treat severe obesity.
According to Novo Nordisk President & CEO Lars Fruergaard Jørgensen, the obesity treatment market may be facing an actual game changer, if the firm successfully obtains the necessary approval for using semaglutide as a medicine against obesity this year.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.